Category: us corporate news

us corporate news

iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1

Minichart

March 9, 2026

iBio, Inc. Announces Promising Preclinical Results for IBIO-...

Continue Reading 0

us corporate news

Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program

Minichart

March 9, 2026

Boundless Bio Reports Q4 and FY2025 Results and Clinical Upd...

Continue Reading 0

us corporate news

Duke Energy Announces $1 Billion Convertible Senior Notes Offering to Refinance 2026 Debt

Minichart

March 9, 2026

Duke Energy Announces Proposed \$1 Billion Convertible Senio...

Continue Reading 0

us corporate news

enCore Energy Reports 2025 Year-End Results: Strong Uranium Production, Improved Financials, and U.S. Project Advancements

Minichart

March 9, 2026

enCore Energy Corp. Reports 2025 Year-End Financials and Pro...

Continue Reading 0

us corporate news

Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Minichart

March 9, 2026

Relmada Therapeutics Reports Promising 12-Month Phase 2 Data...

Continue Reading 0

us corporate news

3D Systems Corporation Reports 2025 Financial Results: Revenue, Gross Profit, and Segment Performance Analysis

Minichart

March 9, 2026

3D Systems Corporation Reports Q4 and Full Year 2025 Financi...

Continue Reading 0

us corporate news

enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares

Minichart

March 9, 2026

Engene Holdings Inc. – Key Developments in Latest 8-K Filing...

Continue Reading 0

us corporate news

Kalaris Therapeutics TH103: Next-Generation Anti-VEGF for Retinal Diseases Shows Promising Phase 1a Results and Extended Durability 23578

Minichart

March 9, 2026

Kalaris Therapeutics Provides Comprehensive Pipeline Update ...

Continue Reading 0

us corporate news

Dianthus Therapeutics Reports 2025 Financial Results and Advancements in Claseprubart Phase 3 Trials for Autoimmune Diseases

Minichart

March 9, 2026

Dianthus Therapeutics, Inc. (DNTH) Q4 & FY2025 Earnings and ...

Continue Reading 0

us corporate news

Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT for MPS IIIB with FDA, and Secures $50M Growth Capital

Minichart

March 9, 2026

Spruce Biosciences 2025 Results & Corporate Update: Detailed...

Continue Reading 0

Category: us corporate news

Join Our Investing Seminar